FDA’s review of MDMA for PTSD highlights study bias and safety concerns
Enlarge / MDMA is now in the FDA's hands. (credit: Getty | PYMCA/Avalon) The safety and efficacy data on the use of MDMA (aka ecstasy) for post-traumatic stress disorder therapy is "challenging to interpret," the Food and Drug Administration said in a briefing document posted Friday. The agency noted significant flaws in the design of…










